Geron Corp.

Geron Corp.

Geron Corp.

Date Founded




Type of Company


Employees (Worldwide)



IT Consulting & Services
Medical Support Services

Company Description

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Contact Data
Trying to get in touch with decision makers at Geron Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman of the Board, President & Chief Executive Officer

Executive Chairman/Director

Executive Vice President & Chief Operating Officer

Executive Vice President, Chief Business Officer

Executive Vice President, Chief Legal Officer & Corporate Secretary

Executive Vice President, Chief Medical Officer

Principal Accounting Officer, Executive Vice President, Finance, Chief Financial Officer & Treasurer

Executive Vice President, Corporate Strategy & Chief Commercial Officer

Vice President, Pharmacovigilance & Drug Safety

Executive Director & Medical Affairs

Board of Directors

Chairman of the Board, President & Chief Executive Officer at Geron Corp.

Senior Advisor at Warburg Pincus LLC

Director at Personalis, Inc.

Founder, President & Chief Executive Officer at Calithera Biosciences, Inc.

Director at Reform Biologics LLC

Former Chief Financial Officer & Executive Director at Lilly USA LLC

Vice President & Chief Commercial Officer at Reata Pharmaceuticals, Inc.

Paths to Geron Corp.
Potential Connections via
Relationship Science
Geron Corp.
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Ecor1 Capital manages the EcoR1 Capital Fund LP, a fundamental long/short equity hedge fund focusing on investment opportunities in the biotechnology sector. The firm employs an innovative, process-driven approach that is based on a value philosophy which attempts to manage risk in the volatile biotechnology sector. The fund focuses on outliers not typically analyzed as part of value based diligence; human capital in addition to deep scientific and financial analysis. Ecor1 Capital is committed to going beyond the usual monetary investment in companies and engages directly with management to identify opportunities for efficiencies and growth, and where necessary, invests their own human capital resources to help mediate much of the risk that is inherent in the sector. The goal of combining this innovative perspective and process is generation of uncorrelated returns relative to the biotechnology sector and to the overall market.

Details Hidden

Great Point Partners seeks to achieve positive excess returns by investing in publicly traded biotechnology, pharmaceutical and life science companies. The firm focuses on creating a balanced portfolio comprised primarily of companies that are undervalued by the public markets. Their hedge funds employ a bottom-up research-driven approach to investing in the securities of undervalued, publicly-traded healthcare companies. Great Point Partners targets fast-growing, technology- driven small-cap companies. In addition, the firm manages private equity funds that invest in private, primarily profitable, lower middle-market, growing healthcare companies.

Recent Transactions
Details Hidden

Geron Corp. issued . USD Common Stock and Warrants

Details Hidden

Geron Corp. issued USD Common Stock

Details Hidden

Geron Corp. issued USD Common Stock

Transaction Advisors

Advised onGeron Corp. issued USD Common Stock

Escrow Agent

Advised onGeron Corp. issued . USD Common Stock and Warrants


Advised onGeron Corp. issued . USD Common Stock and Warrants

Legal Advisor

Advised onGeron Corp. issued . USD Common Stock and Warrants

Legal Advisor

Advised onGeron Corp. issued USD Common Stock

Managing Director

Advised onGeron Corp. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Latham & Watkins LLP

Legal Advisor

Partner at Morrison & Foerster LLP


Founder at Sosei Group Corp.


Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Oncolys BioPharma, Inc. engages in the research and development of cancer treatment therapy and diagnostics which include early detection, loco-regional therapy, prognostic test, and systemic treatments. It operates through the Pharmaceutical and Diagnostics segments. The Pharmaceutical segment deals with the research, development, manufacture, and sale of pharmaceutical products. The Diagnostics segment engages in the research, development, manufacture, and sale of test agents and equipment as well as the provision of testing services. The company was founded by Yasuo Urata on March 18, 2004 and is headquartered in Tokyo, Japan.

Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA.

Key Stats and Financials As of 2020
Market Capitalization
Total Enterprise Value
Earnings Per Share
Enterprise Value / Sales
TEVNet Income
Debt TEV
Total Equity
Total Debt
Net Profit
Three Year Compounded Annual Growth Rate Of Revenue
Non-Profit Donations & Grants
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Geron Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Geron Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Geron Corp..